As far as Genome Canada is concerned, we solved that problem a long time ago. The names of reviewers are not disclosed. We disclose the names of all members of the panel. The research scientist does not know who will assess and validate his or her file. There is an advantage in this: the scientist could tell you, for example, that you have a conflict of interest regarding his application, but tell Mr. Tonks that he has none. The researcher has the opportunity, two weeks before the assessment, to tell Genome Canada, for example, sorry, but such and such a reviewer has a conflict of interest in terms of disclosure. This is a very transparent approach.
Reviewers' reports are anonymous, in other words no one knows who wrote them. But they are made public. Anyone, at the request of the minister, can get information on the report. We cannot post them on the Web, because we are talking about 4,000 pages. It has already happened: Minister Emerson, at the time, requested, under the Access to Information Act, a specific piece of information. We accepted and asked the researcher if he had any objection. It was anonymous, and so we provided the information that he needed.
We can go pretty far in terms of transparency, without getting into a conflict of interest and without breaching confidentiality.